Almirall's 16th Skin Academy: Pioneering Skin Science and Treatment

In the ever-evolving landscape of medical dermatology, Almirall's 16th Skin Academy stands as a beacon of innovation and collaboration. This premier conference, held in Barcelona, Spain, brings together leading experts from across the globe to advance science and innovative approaches for the treatment of skin diseases. The event, which features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practices, is a testament to Almirall's commitment to medical dermatology.

The 16th Skin Academy is more than just a conference; it is a unique opportunity for collaboration. By bringing together a broad range of leading experts and clinicians, the event fosters a network of peers that discuss and learn together to advance the treatment of skin diseases. This year's event is expected to attract over 800 participants, led by international experts, with common interests to create a network to discuss, educate, and learn to advance knowledge in medical dermatology.

One of the key areas of focus at the 16th Skin Academy is the holistic and personalized treatment of atopic dermatitis and psoriasis. Atopic dermatitis, a highly prevalent and debilitating condition, will be a central focus at the conference. Experts will offer new insights into its pathophysiology, the role of IL-13, and the importance of advanced treatment protocols. The discussion will include a comprehensive analysis of the efficacy and safety of leading treatments over time, as well as real-world evidence from clinical practice. Another key topic is the dermatologist-patient relationship, which is crucial for treatment success, especially based on the role of shared decision-making in treatment planning.



Psoriasis will be another focus area for the 16th Skin Academy, with sessions dedicated to biologic treatments. Speakers will address unmet medical needs, the importance of individualized treatment for long-term disease control, and share real-world evidence showing the effectiveness and safety of targeted IL-23 inhibition. The conference will also highlight the importance of striving for patient wellbeing as a treatment outcome. Additionally, current treatment challenges and approaches to address difficult-to-treat areas of the skin, including advancements in topical treatments and new efficacy data with IL-23 inhibition in psoriasis of the scalp, will be discussed.

The comprehensive program of the 16th Skin Academy covers a broad range of skin diseases such as actinic keratosis, androgenetic alopecia, onychomycosis, and chronic spontaneous urticaria. This focus on various skin diseases aims to advance the understanding of these conditions and treatment options to support better patient outcomes.

Prof. Dr. Ulrich Mrowietz from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kiel in Germany, stated, "deep collaboration across experts is essential for advancing medical dermatology and providing better treatment outcomes for patients. Almirall’s Skin Academy provides a unique platform for practitioners to explore latest scientific advances, clinical practice and discuss a broad range of skin diseases, with an emphasis on holistic, personalized patient care and wellbeing."

The Chief Medical Officer of Almirall, Dr. Volker Koscielny, highlighted the event's significance by saying, "this is the 16th edition of the Skin Academy, and we are proud to continue to provide a leading platform for exchange and advancement in medical dermatology. Partnering with the dermatology community across Europe is based on our unique focus on medical dermatology and supported by our R&D capabilities as well as our strong collaborations. Skin Academy fosters collaboration and co-creation of innovative approaches and solutions that help the medical dermatology community to better respond to the unmet needs of millions of people living with these conditions."

In summary, Almirall's 16th Skin Academy is expected to contribute to the advancement of medical dermatology by facilitating the exchange of knowledge, fostering collaboration, and promoting the development of innovative treatment options for a wide range of skin diseases. The event is a testament to Almirall's commitment to educational advancement and its dedication to improving patient outcomes through cutting-edge research and collaboration.